For research use only. Not for therapeutic Use.
Oteseconazole（Cat No.:I008515）, also known as VT-1161, is a potent antifungal agent that is administered orally. It exhibits strong binding and inhibition of the CYP51 enzyme in Candida albicans, a fungus responsible for fungal infections. Oteseconazole effectively targets the fungal CYP51 enzyme with a binding affinity (Kd) of less than 39 nM, thereby hindering the growth and proliferation of the Candida albicans fungus. Importantly, it has minimal impact on the human CYP51 enzyme, reducing the potential for adverse effects on human metabolism.
| Catalog Number | I008515 |
| CAS Number | 1340593-59-0 |
| Synonyms | Oteseconazole; VT-1161; VT 1161; VT1161.;(R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol |
| Molecular Formula | C23H16F7N5O2 |
| Purity | 98% |
| Target | CYP51 |
| Target Protein | P10613 |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | Kd:<39 nM(CYP51) |
| IUPAC Name | (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol |
| InChI | InChI=1S/C23H16F7N5O2/c24-16-4-7-18(19(25)9-16)21(36,11-35-13-32-33-34-35)23(29,30)20-8-3-15(10-31-20)14-1-5-17(6-2-14)37-12-22(26,27)28/h1-10,13,36H,11-12H2/t21-/m0/s1 |
| InChIKey | IDUYJRXRDSPPRC-NRFANRHFSA-N |
| SMILES | C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F |
| Reference | </br> 1:Gupta AK, Studholme C. Novel investigational therapies for onychomycosis: an update. Expert Opin Investig Drugs. 2016;25(3):297-305. doi: 10.1517/13543784.2016.1142529. Review. PubMed PMID: 26765142.</br> 2:Hoekstra WJ, Hargrove TY, Wawrzak Z, da Gama Jaen Batista D, da Silva CF, Nefertiti AS, Rachakonda G, Schotzinger RJ, Villalta F, Soeiro Mde N, Lepesheva GI. Clinical Candidate VT-1161/’s Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi. Antimicrob Agents Chemother. 2015 Dec 7;60(2):1058-66. doi: 10.1128/AAC.02287-15. PubMed PMID: 26643331; PubMed Central PMCID: PMC4750653. |
